March 2, 2026 /
Researchers are committed to finding solutions for everyone affected by MS. Without participants—like you—in research studies, MS research would come to a standstill. Most studies have limited space.
| Study Sponsor Immune Tolerance Network |
| Qualifications for Participation Participants should be ages 18 to 55, diagnosed with MS, and experiencing highly active, treatment-resistant relapsing MS, defined as two or more episodes of disease activity in the prior 36 months, at least one of which must have occurred while taking medication for MS. Location of Study Nationwide Study Objective Investigators are recruiting 110 people with relapsing MS (relapsing-remitting MS or secondary progressive MS with relapses) at 19 sites nationwide for a pivotal clinical trial comparing autologous hematopoietic stem cell transplantation (AHSCT, also commonly known as HSCT) to disease-modifying therapies that have been shown to be the most highly effective in people with MS. |
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
